CCR3-Targeted Quantum Dots for Early CNV Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration (AMD) caused by choroidal neovascularization (CNV) are limited in effectiveness, with VEGF-A antagonists providing only partial vision improvement and safety concerns, and lack a specific molecular marker for targeting CNV.
Innovation Solution
Targeting the CCR3 receptor and its ligands, such as eotaxins, which are specifically expressed in CNV tissues, using neutralizing antibodies or receptor antagonists to inhibit angiogenesis, and using CCR3-targeted quantum dots for early detection of CNV.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If VEGF-A antagonists are used to treat CNV, then CNV progression is inhibited, but vision improvement is limited and safety concerns arise
Solution Approach 1:
The patent applies local quality by using CCR3-targeted quantum dots that specifically bind to CCR3 receptors expressed only on CNV endothelial cells, not on normal retinal vessels. This enables localized detection and treatment of CNV while preserving normal retinal function, resolving the contradiction between treatment effectiveness and safety
Solution Approach 2:
The patent segments the detection and treatment approach by using CCR3 as a specific molecular marker that distinguishes CNV from normal vasculature. This segmentation allows selective targeting of pathological vessels while sparing healthy tissue, improving both effectiveness and safety
2Measurement precision
If CCR3-targeted quantum dots are used for detection, then early CNV detection is enabled, but detection of subretinal CNV becomes possible only with specific molecular markers
Solution Approach 1:
The patent uses CCR3 as an intermediary molecular marker that mediates between the quantum dot probe and the CNV endothelial cells. The CCR3 receptor serves as a specific binding target that enables the quantum dots to detect CNV with high sensitivity and precision, overcoming the difficulty of detecting subretinal CNV without specific markers
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
CCR3 targeting effectively reduces CNV progression independently of inflammation and is more effective than VEGF-A blockade, with CCR3-targeted bioimaging enabling early detection before retinal invasion, offering a safer and more effective treatment option for AMD.
Implementation Method 1
The invention utilizes biocompatible quantum dots or other bioimaging fluorochromes (e.g., near infrared dyes) to detect CCR3 on choroidal endothelial cells
Implementation Method 2
CCR3-targeted quantum dots detect subretinal choroidal neovascularization (CNV)
Data Source
AI summary
The results presented herein demonstrate the specific expression of CCR3 in CNV endothelial cells in humans with AMD, and despite the expression of its ligands, eotaxin-1, -2, and -3, neither eosinophils nor mast cells are present in human CNV. The genetic or pharmacological targeting of CCR3 or eotaxins as disclosed herein inhibited injury-induced CNV in mice. CNV suppression by CCR3 blockade was due to direct inhibition of endothelial cell proliferation, and was uncoupled from inflammation as it occurred in mice lacking eosinophils or mast cells and was independent of macrophage and neutrophil recruitment. CCR3 blockade was more effective at reducing CNV than vascular endothelial growth factor-A (VEGF-A) neutralization, which is currently in clinical use, and, unlike VEGF-A blockade, not toxic to the mouse retina. In vivo imaging with CCR3-targeting quantum dots located spontaneous CNV invisible to standard fluorescein angiography in mice before retinal invasion. CCR3 targeting is useful in reducing vision loss due to AMD through early detection and therapeutic angioinhibition.